These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 27678175)

  • 21. Nanoparticles-based delivery system and its potentials in treating central nervous system disorders.
    Liu T; Xie Q; Dong Z; Peng Q
    Nanotechnology; 2022 Aug; 33(45):. PubMed ID: 35917704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transcellular brain drug delivery: A review on recent advancements.
    Azarmi M; Maleki H; Nikkam N; Malekinejad H
    Int J Pharm; 2020 Aug; 586():119582. PubMed ID: 32599130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theranostical application of nanomedicine for treating central nervous system disorders.
    Ran W; Xue X
    Sci China Life Sci; 2018 Apr; 61(4):392-399. PubMed ID: 29675554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanomedicine for the treatment of Alzheimer's disease.
    Gregori M; Masserini M; Mancini S
    Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis.
    Posadas I; Monteagudo S; Ceña V
    Nanomedicine (Lond); 2016 Apr; 11(7):833-49. PubMed ID: 26980585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging Use of Nanotechnology in the Treatment of Neurological Disorders.
    Chhabra R; Tosi G; Grabrucker AM
    Curr Pharm Des; 2015; 21(22):3111-30. PubMed ID: 26027574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases.
    Ceña V; Játiva P
    Nanomedicine (Lond); 2018 Jul; 13(13):1513-1516. PubMed ID: 29998779
    [No Abstract]   [Full Text] [Related]  

  • 29. Frontier View on Nanotechnological Strategies for Neuro-therapy.
    Azhar A; Ashraf GM; Zia Q; Ansari SA; Perveen A; Hafeez A; Saeed M; Kamal MA; Alexiou A; Ganash M; Yarla NS; Baeesa SS; Alfiky MM; Bajouh OS
    Curr Drug Metab; 2018; 19(7):596-604. PubMed ID: 29512448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers.
    Poovaiah N; Davoudi Z; Peng H; Schlichtmann B; Mallapragada S; Narasimhan B; Wang Q
    Nanoscale; 2018 Sep; 10(36):16962-16983. PubMed ID: 30182106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of modelling and nanotechnology-based approaches: The emergence of breakthroughs in theranostics of central nervous system disorders.
    Hassanzadeh P; Atyabi F; Dinarvand R
    Life Sci; 2017 Aug; 182():93-103. PubMed ID: 28583367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
    Dilnawaz F; Sahoo SK
    Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
    Peluffo H; Unzueta U; Negro-Demontel ML; Xu Z; Váquez E; Ferrer-Miralles N; Villaverde A
    Biotechnol Adv; 2015; 33(2):277-87. PubMed ID: 25698504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
    Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
    Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS.
    Gondim BLC; da Silva Catarino J; de Sousa MAD; de Oliveira Silva M; Lemes MR; de Carvalho-Costa TM; de Lima Nascimento TR; Machado JR; Rodrigues V; Oliveira CJF; Cançado Castellano LR; da Silva MV
    Curr Pharm Des; 2019; 25(37):3983-3996. PubMed ID: 31612822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities.
    Li H; Guan M; Zhang NN; Wang Y; Liang T; Wu H; Wang C; Sun T; Liu S
    Biomed Pharmacother; 2024 Aug; 177():117011. PubMed ID: 38917758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymeric nanoparticles for the drug delivery to the central nervous system.
    Tosi G; Costantino L; Ruozi B; Forni F; Vandelli MA
    Expert Opin Drug Deliv; 2008 Feb; 5(2):155-74. PubMed ID: 18248316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chapter 3 - Colloidal systems for CNS drug delivery.
    Costantino L; Tosi G; Ruozi B; Bondioli L; Vandelli MA; Forni F
    Prog Brain Res; 2009; 180():35-69. PubMed ID: 20302828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in nanomedicines for diagnosis of central nervous system disorders.
    Zhang X; Zhou J; Gu Z; Zhang H; Gong Q; Luo K
    Biomaterials; 2021 Feb; 269():120492. PubMed ID: 33153757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.